Introduction {#sec1}
============

[l]{.smallcaps}-Threonine is an essential amino acid for mammals and has a wide spectrum of commercial uses, such as a food additive and agricultural feed supplement. Mainly produced through microbial fermentation of *Escherichia coli*, considerable efforts have been directed toward more efficient production of [l]{.smallcaps}-threonine via metabolic engineering.^[@ref1]^ From [l]{.smallcaps}-aspartate, the biosynthesis of [l]{.smallcaps}-threonine comprises five successive reactions sequentially catalyzed in *Corynebacterium glutamicum* by aspartate kinase (LysC), aspartyl semialdehyde dehydrogenase (Asd), homoserine dehydrogenase (Hom), homoserine kinase (ThrB), and threonine synthase (ThrC) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).

![Biosynthetic pathway of [l]{.smallcaps}-threonine and its regulation in *C. glutamicum*. [l]{.smallcaps}-Threonine regulates its own biosynthetic pathway by allosterically inhibiting aspartate kinase (LysC) and homoserine dehydrogenase (Hom) in a noncompetitive manner and homoserine kinase (ThrB) as a competitive inhibitor (shown in broken lines). Solid lines indicate branch pathways related to the [l]{.smallcaps}-threonine biosynthetic pathway.](ao-2017-015977_0005){#fig1}

The level of [l]{.smallcaps}-threonine production in *C. glutamicum* is tightly regulated in four different ways ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). First, available carbon flux is routed from [l]{.smallcaps}-threonine biosynthesis mainly toward the competing [l]{.smallcaps}-lysine and [l]{.smallcaps}-methionine metabolic pathways.^[@ref2]^ Second, intracellular [l]{.smallcaps}-threonine is depleted through the production of [l]{.smallcaps}-isoleucine and glycine.^[@ref3]−[@ref6]^ Third, both the *hom* and *thrB* genes in *C. glutamicum* are clustered in a single operon that is repressed by [l]{.smallcaps}-methionine, possibly by a transcriptional attenuation-like regulation mechanism.^[@ref7],[@ref8]^ Finally, three enzymes in the biosynthetic pathway of [l]{.smallcaps}-threonine are regulated by feedback inhibition: homoserine dehydrogenase (Hom) is subject to feedback inhibition by [l]{.smallcaps}-threonine and aspartate kinase (LysC) by both [l]{.smallcaps}-lysine and [l]{.smallcaps}-threonine. These two enzymes are inhibited by [l]{.smallcaps}-threonine in an allosteric noncompetitive manner, whereas homoserine kinase (ThrB) is inhibited by [l]{.smallcaps}-threonine in a competitive inhibitory mechanism.^[@ref9]−[@ref11]^

To afford higher levels of [l]{.smallcaps}-threonine production, several metabolic engineering strategies have been implemented. First, overexpression of the *hom*^*r*^*-thrB* operon that includes a feedback-resistant homoserine dehydrogenase allele is a strategy that has been one of the most successful ones to redirect the carbon flux from the [l]{.smallcaps}-lysine branch into the [l]{.smallcaps}-threonine branch, leading to the accumulation of both [l]{.smallcaps}-threonine and [l]{.smallcaps}-homoserine.^[@ref12],[@ref13]^ The second strategy has been to reduce [l]{.smallcaps}-threonine depletion toward [l]{.smallcaps}-isoleucine and glycine by mutation of both *glyA* and *ilvA* responsible for the conversion of [l]{.smallcaps}-threonine into glycine and [l]{.smallcaps}-isoleucine, respectively.^[@ref14]^ Another strategy was to enhance the efflux of [l]{.smallcaps}-threonine, which typically accumulates in the cell and thus downregulates the biosynthetic enzymes in a feedback manner.^[@ref4],[@ref15]^ Both the introduction of a recombinant plasmid containing the permease *thrE* gene and the overexpression of the *E. coli* genes *rhtA*, *rhtC*, and *yeaS*, previously inserted into *C. glutamicum*, lead to an increased production of [l]{.smallcaps}-threonine and a decrease in accumulation of [l]{.smallcaps}-lysine, glycine, [l]{.smallcaps}-isoleucine, and [l]{.smallcaps}-homoserine.^[@ref4],[@ref15]−[@ref17]^

As described above, there are three enzymes (LysC, Hom, and ThrB) in the [l]{.smallcaps}-threonine biosynthetic pathway that are feedback inhibited by the end-product [l]{.smallcaps}-threonine ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Among these, feedback-resistant mutations were successfully made in genes encoding for LysC and Hom and overexpression of these mutant alleles resulted in a 3.5-fold higher production of [l]{.smallcaps}-threonine in *C. glutamicum*.^[@ref12],[@ref13]^ However, it has been difficult to produce feedback-resistant homoserine kinase because [l]{.smallcaps}-threonine inhibits the enzyme in a competitive manner with the substrate [l]{.smallcaps}-homoserine.^[@ref11]^ Therefore, mutations that block the binding of [l]{.smallcaps}-threonine at the active site would also inhibit the binding of [l]{.smallcaps}-homoserine and thus severely diminish the enzymatic activity of the enzyme.

In this report, an attempt was made to render the active site of *C. glutamicum* ThrB (*Cgl*ThrB) more selective toward [l]{.smallcaps}-homoserine than [l]{.smallcaps}-threonine. First, we successfully crystallized *Cgl*ThrB-WT with a resolution of 2.2 Å. Aligning this structure with the archaea *Methanocaldococcus jannaschii* ThrB (*Mja*ThrB) X-ray crystal structure that was solved with both homoserine and threonine, we hypothesized that alanine 12 in *Mja*ThrB (A20 in *Cgl*ThrB) may support the binding of [l]{.smallcaps}-threonine and that the alteration of the residue might affect the binding of [l]{.smallcaps}-threonine without affecting that of [l]{.smallcaps}-homoserine. To test this possibility, we mutated A20 in *Cgl*ThrB to various amino acid residues; we tested the enzymatic activity of these variants. The *C. glutamicum* ThrB-A20G (*Cgl*ThrB-A20G) showed a similar activity as wild-type ThrB (*Cgl*ThrB-WT), whereas other mutations abolished or greatly diminished the activity. Subsequent inhibition assays showed that *Cgl*ThrB-A20G was less inhibited by [l]{.smallcaps}-threonine compared with *Cgl*ThrB-WT. Taken together, we have successfully released competitive feedback inhibition of *Cgl*ThrB without losing much of the enzymatic activity via structural analysis and site-specific mutation.

Results {#sec2}
=======

Identification and Role of the Conserved ThrB Active-Site Residues {#sec2.1}
------------------------------------------------------------------

The enzymes of the galactokinase, homoserine kinase, mevalonate kinase, and phosphomevalonate kinase (GHMP) family possess three conserved structural motifs, motif I, II, and III ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).^[@ref18]^ Two additional motifs are known to be important for the binding amino acid substrate or inhibitor in ThrB, the lower and upper lips.^[@ref19],[@ref20]^ Of these motifs, motif I is the only motif directly interacting with the side chains of the [l]{.smallcaps}-homoserine substrate or [l]{.smallcaps}-threonine inhibitor, thereby allowing potential discrimination between the branched inhibitor, [l]{.smallcaps}-threonine, and the linear substrate, [l]{.smallcaps}-homoserine. To determine the exact position of that conserved motif in *C. glutamicum* ThrB, we performed a pairwise protein sequence alignment using the ThrB sequences encoded by *E. coli* and *Mycobacterium tuberculosis*. Because X-ray crystal structures of the *M. jannaschii*-encoded ThrB in complex with [l]{.smallcaps}-threonine and [l]{.smallcaps}-homoserine have been solved (PDB codes: 1H73 and 1H72, respectively), the *M. jannaschii* ThrB sequence was also used in the alignment ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).^[@ref19]^ A conserved amino acid sequence, −SSAN--, in motif I was identified in this alignment.

![(A) Alignment of *C. glutamicum* homoserine kinase (*Cgl*ThrB) sequence with those of *E. coli*, *M. jannaschii*, and *M. tuberculosis* using CLUSTAL O (1.2.4). Conserved residues are shown with asterisk (\*), residues with strongly similar properties are shown with a colon (:), and residues with weakly similar properties are shown with a period (.). The conserved Ala residues in motif I are highlighted in yellow. The arrows represent β-strands, whereas the ovals represent α-helices. (B) Structure of *C. glutamicum* ThrB (*Cgl*ThrB-WT) with modeled [l]{.smallcaps}-homoserine and AMP-PNP based on the structure of *M. jannaschii* ThrB, with these compounds bound in the active site.](ao-2017-015977_0003){#fig2}

A full-length structure of *Cgl*ThrB-WT was solved at 2.2 Å resolution. Aligning that structure with the X-ray crystal structure of *M. jannaschii* in complex with [l]{.smallcaps}-threonine and [l]{.smallcaps}-homoserine ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B,C, respectively), it was confirmed that the active sites of the two proteins were structurally similar and that the alanine (A12) of that motif was the only residue directly interacting with the side-chain methyl moiety of [l]{.smallcaps}-threonine. Thus, the conserved alanine residue (A20) in motif I of *C. glutamicum* ThrB offered the highest potential for producing ThrB variants exhibiting enhanced selectivity of [l]{.smallcaps}-threonine over [l]{.smallcaps}-homoserine ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A).

![Interactions of *C. glutamicum* ThrB (A in cyan) or *M. jannaschii* ThrB (B and C in green) between binding site amino acids and substrates or ligands. (A) A phosphate anion is bound in the active site of *Cgl*ThrB-WT, preventing binding of substrates or inhibitors within the amino acid binding site. (B) [l]{.smallcaps}-homoserine bound into the active site of *M. jannaschii* ThrB (PDB: 1H72). (C) [l]{.smallcaps}-threonine bound into the active site of *M. jannaschii* ThrB (PDB: 1H73).](ao-2017-015977_0009){#fig3}

There are multiple strategies to retain wild-type ThrB activity while decreasing affinity for the competitive inhibitor, [l]{.smallcaps}-threonine. One strategy is to engineer new interactions that support substrate binding but weaken inhibitor binding. For example, one can retain hydrophobicity of the active site responsible for binding the ethyl moiety of the [l]{.smallcaps}-homoserine side chain but add steric bulk at position A20 in *C. glutamicum* (corresponding to A12 in *Mja*ThrB), promoting steric hindrance with the methyl branch of the [l]{.smallcaps}-threonine side chain. To test this strategy, A20 of *Cgl*ThrB was mutated into either a valine or a leucine residue. A second strategy to test the importance of A20 and its role in substrate/inhibitor binding is to change the polarity by creation of a serine mutation. It is the least disrupting variant because it minimizes steric effects. A third strategy is to decrease the strength of the van der Waals interaction between the A20 and the hydrophobic portion of the corresponding substrate/inhibitor side chain. In this case, a glycine mutation that likely weakens van der Waals interactions between the methyl group of [l]{.smallcaps}-threonine and A20 was made to evaluate its importance in selectivity between [l]{.smallcaps}-threonine and [l]{.smallcaps}-homoserine.

*Cgl*ThrB-A20G Mutant Enzyme: As Active As *Cgl*ThrB-WT {#sec2.2}
-------------------------------------------------------

Activity of each purified enzyme was measured in an end-point assay using the ADP Colorimetric/Fluorometric Assay Kit (Sigma-Aldrich). *Cgl*ThrB-A20V and *Cgl*ThrB-A20L lost their activity, but *Cgl*ThrB-A20S retained 44% of the wild-type activity ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). The last mutant, *Cgl*ThrB-A20G showed a similar level of enzymatic activity to *Cgl*ThrB-WT ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

![Enzymatic activity of WT and four variants of *Cgl*ThrB. *Cgl*ThrB-A20G is as active as *Cgl*ThrB-WT. The concentration of ADP (*Y* axis) was determined after incubating each enzyme with [l]{.smallcaps}-homoserine and ATP at 27 °C for 30 min. WT: *Cgl*ThrB-WT, A20G: *Cgl*ThrB-A20G, A20V: *Cgl*ThrB-A20V, A20L: *Cgl*ThrB-A20L, and A20S: *Cgl*ThrB-A20S.](ao-2017-015977_0006){#fig4}

To further assess the enzymatic activity of *Cgl*ThrB-WT and the *Cgl*ThrB-A20G variant and the effect of changing [l]{.smallcaps}-homoserine concentrations, steady-state kinetic experiments were performed with saturating concentrations of ATP. Under these pseudo-first-order conditions, the *K*~m~ for [l]{.smallcaps}-homoserine in *Cgl*ThrB-A20G was determined to be only 2-fold higher than the *K*~m~ of *Cgl*ThrB-WT and resulting in only a 35% decrease in the specificity constant ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}).

![Kinetic reaction rates in the presence of 0, 10, 20, and 50 mM [l]{.smallcaps}-threonine of *Cgl*ThrB-WT and *Cgl*ThrB-A20G variant. Each datum represents the value of three determinations (*n* = 3). [l]{.smallcaps}-Threonine concentration: ●: 0 mM, ○: 10 mM, ▼: 20 mM, and ∇: 50 mM.](ao-2017-015977_0007){#fig5}

*Cgl*ThrB-A20G Exhibits Reduced Feedback Inhibition by [l]{.smallcaps}-Threonine {#sec2.3}
--------------------------------------------------------------------------------

Because *Cgl*ThrB-A20G was the only mutant retaining wild-type activity, that variant was tested for changes in negative feedback inhibition by [l]{.smallcaps}-threonine in an end-point assay ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}) and steady-state enzyme kinetics ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). *Cgl*ThrB-WT exhibits a *K*~i~ of 4.73 mM, whereas *Cgl*ThrB-A20G showed an approximately 5.4-fold higher *K*~i~ for [l]{.smallcaps}-threonine, with a final value of 25.22 mM ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). For example, the 5 mM [l]{.smallcaps}-Threonine inhibited wild-type ThrB activity by 40% but inhibited *Cgl*ThrB-A20G by only 16% ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). [l]{.smallcaps}-Threonine (10 mM), which is unlikely to occur in vivo, inhibits 65% of *Cgl*ThrB-WT activity but it only inhibits 38% of *Cgl*ThrB-A20G activity.

![*Cgl*ThrB-A20G has eliminated much of the feedback inhibition while retaining wild-type enzymatic activity. The reaction conditions were the same as those in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"} except that different concentrations of [l]{.smallcaps}-threonine (0, 5, 10, and 20 mM) were used.](ao-2017-015977_0008){#fig6}

Structural Analysis of CglThrB-WT {#sec2.4}
---------------------------------

As mentioned previously ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}), homoserine kinases have five important regions interacting with their substrate and inhibitor. The first structure of *Cgl*ThrB-WT solved at 1.8 Å resolution displays hydrolysis of the upper lip as well as the helix stabilizing it, suggesting it could have an important role in binding the substrate/inhibitor ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}).

![Hydrolyzed structure of *Cgl*ThrB-WT (gold) superimposed with the full-length *Cgl*ThrB-WT (cyan) containing modeled [l]{.smallcaps}-homoserine and AMP-PNP from 1H72.](ao-2017-015977_0002){#fig7}

The full-length structure was solved at 2.2 Å resolution and exhibited high *B*-factors for residues of both the upper and lower lips. This fully intact structure of *Cgl*ThrB-WT was obtained with three phosphate or sulfate ions in the active site. One anion is bound in the amino acid binding site interacting with R240, N21, and D27, which are conserved residues required for coordinating both the α-carboxylate moiety and the α-amino moiety of amino acid substrate or inhibitors ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). The other two ions directly interact with the P-loop.^[@ref21]^ Additionally, a magnesium ion is present in the active site, resulting in the displacement of the lower lip ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}).

![Significant shift of the lower lip that interacts with both magnesium and the amino acid present in the active site. (A) *M. jannaschii* ThrB-WT with [l]{.smallcaps}-isoleucine, magnesium (purple sphere) and ATP-γS bound into its active site (PDB: 1H74). (B) *Cgl*ThrB-WT with magnesium (purple sphere) and three phosphate/sulfate bound in the active site. The omit map of all three phosphates/sulfates is contoured to 3σ. (C) Superposition of both *M. jannaschii* and *Cgl*ThrB-WT with both their magnesium (purple spheres) and [l]{.smallcaps}-isoleucine and ATP-γS from 1H74.](ao-2017-015977_0004){#fig8}

Discussion {#sec3}
==========

To promote higher levels of [l]{.smallcaps}-threonine production by fermentation of *C. glutamicum*, the negative feedback inhibition of ThrB by [l]{.smallcaps}-threonine needs to be suppressed. After analyses of the available structures from *M. jannaschii* in complex with both the end-product inhibitor, [l]{.smallcaps}-threonine, and the natural substrate, [l]{.smallcaps}-homoserine, the alanine 12 residue, was identified as being the only amino acid present in the active site that would allow for discrimination of the substrate and competitive inhibitor by the enzyme. To determine the impact of varying the conserved alanine (A20) in *C. glutamicum* ThrB, the A20 residue was mutated into a leucine and a valine. These mutations were meant to introduce a steric hindrance, preventing binding of [l]{.smallcaps}-threonine while still affording the binding of the [l]{.smallcaps}-homoserine substrate. Another mutation to a serine residue was also performed to introduce polarity into the active site, creating an unfavorable environment that rendered the active site less compatible to binding of the hydrophobic methyl moiety of the [l]{.smallcaps}-threonine side chain. A final mutation into a glycine was also introduced with the rationale that this mutation may suppress a low-energy van der Waals interaction between the methyl group of [l]{.smallcaps}-threonine and the alanine side chain, which is an interaction that does not occur when [l]{.smallcaps}-homoserine binds within the active site.

It was shown in the end-point enzyme assay that while mutations to either leucine or valine resulted in complete loss of activity, the serine variant lost only 47% of WT activity. This suggests that the steric hindrance between the amino acid ligand and the side chain at position 20 of *Cgl*ThrB has a more significant detrimental impact on enzymatic activity than a change in polarity at this position of the active site. This is likely due to weakening of binding of the [l]{.smallcaps}-homoserine amino acid in the A20L and A20V variants due to steric hindrance that does not occur in the A20S variant. Alternatively, these variants may still bind the substrate but the side-chain hydroxyl moiety of [l]{.smallcaps}-homoserine is then positioned in a location or an orientation that disallows attack on the γ-phosphate of ATP. The last variant, *Cgl*ThrB-A20G, retained complete WT activity. The subsequent assays with [l]{.smallcaps}-threonine showed a dramatic loss of negative feedback inhibition in *Cgl*ThrB-A20G, with a *K*~i~ that is 5.3-fold lower than that of *Cgl*ThrB-WT. Because we determined the activity of *Cgl*ThrB-A20G by measuring ADP production, not *o*-phosphohomoserine production, we cannot rule out the possibility that A20G mutation simply affords the hydrolysis of ATP instead of phosphoryl transfer to [l]{.smallcaps}-homoserine.

To investigate further the interaction of [l]{.smallcaps}-threonine and [l]{.smallcaps}-homoserine with the active site of *Cgl*ThrB, the protein was crystallized. Interestingly, the first apo structure that was solved at 1.8 Å, showed hydrolysis of the upper lip as well as the α-helix directly adjacent due to structural dynamics in that region, as later evidenced by elevated *B*-factors in the analogous region of the full-length protein structure ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}). A full-length structure solved at 2.2 Å also shows high dynamicity of the upper and lower lip with high *B*-factors in these regions. Additionally, crystallization of both *Cgl*ThrB-A20G and *Cgl*ThrB-A20V has been attempted. However, the mutations seem to either destabilize the active site or increase flexibility in the active site, thereby suppressing crystallization.

Because only apo structures of *Cgl*ThrB-WT (PDB: 5WAT) were obtained, interactions between the enzymes and the amino acid substrates or inhibitors can only be inferred from interactions observed in the *M. jannaschii* ThrB structures. However, three sulfate/phosphate molecules are present in the active site and exhibit interactions with the *Cgl*ThrB enzyme that are similar to the interactions of amino acids with the *M. jannaschii* active site. For instance, both N13 and R231 form identical interactions with the sulfate present in the *Cgl*ThrB-WT structure that are analogous to interactions formed by these conserved active site residues with the carboxylic acid moiety of the amino acid present in *M. jannaschii*. Similarly, N21 and D27 form interactions with the sulfate present in the *Cgl*ThrB-WT that are comparable to interactions between *Mja*ThrB-WT and the amino moiety of the amino acid substrate or inhibitor. Differences were, however, observed. For example, a 1.0 to 1.7 Å shift was observed in the position of the D139 side chain, resulting from the absence of interactions with the amino moiety of the substrate ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). In a similar manner, the lack of interaction between R194 and the carboxylic moiety of the amino acid results in the R194 side chain interacting with solvent ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Additionally, although the magnesium in *Mja*ThrB-WT is interacting with the phosphate of APTγS and the lower lip, it is solvent-exposed in *Cgl*ThrB-WT and is coordinated by the lower lip, resulting in interactions with the two sulfates present in the ATP binding site. This further supports the high dynamicity of the active site of actinobacterial ThrB.

In conclusion, we have demonstrated that a single mutation at a conserved residue at the active site in homoserine kinase decreases the feedback inhibition by [l]{.smallcaps}-threonine while maintaining the enzymatic activity. To our knowledge, this was the first case where competitive feedback inhibition was successfully released via structural analysis and site-specific mutation. A similar approach may be used to create feedback-insensitive mutants in other biosynthetic enzymes. Additionally, competitive inhibitors that bind to ThrB homolog of medically important bacterial pathogens may be designed on the basis of these determined structures.

Materials and Methods {#sec4}
=====================

Primary Structure Alignment of Homoserine Kinase from *E. coli*, *C. glutamicum*, *M. tuberculosis*, and *M. jannaschii* {#sec4.1}
------------------------------------------------------------------------------------------------------------------------

The alignment used to determine conserved motifs and amino acids of interest to our study was performed using Clustal Omega.^[@ref22],[@ref23]^ The Uniprot codes for the respective proteins are P00547, I6Y665, A0A072ZHQ8, and Q58504.

Bacterial Strains and Growth Conditions {#sec4.2}
---------------------------------------

*E. coli* Top 10 (Invitrogen) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) was used as a cloning host and *E. coli* BL21 (DE3) for expression of recombinant proteins and for the determination of [l]{.smallcaps}-threonine production. Cultures were grown at 37 °C in Luria-Bertani (LB) broth or solid medium with chloramphenicol (34 μg/mL).

###### Strains and Plasmids Used in This Work

                    description                                                                   reference or source                                                                                    
  ----------------- ----------------------------------------------------------------------------- --------------------------------------------------------------- -------------------------------------- ------------
  strain            *E. coli*                                                                     Top 10                                                          *E. coli* host for molecular cloning   Invitrogen
  BL21 (DE3)        *E. coli* host for protein expression                                         Invitrogen                                                                                             
  *C. glutamicum*   ATCC 13032                                                                    genomic DNA as a template for polymerase chain reaction (PCR)   ATCC                                   
  plasmid           pACYCDuet-1                                                                   duel expression vector (Cm^r^)                                  Invitrogen                             
  pCK448            pACYCDuet-1 carrying *C. glutamicumthrB*-*6his* under P~T7~                   in house                                                                                               
  pCK449            pACYCDuet-1 carrying *C. glutamicumthrBA16G*-*6his* under P~T7~               in house                                                                                               
  pCK450            pACYCDuet-1 carrying *C. glutamicumthrBA16V*-*6his*, this study under P~T7~   in house                                                                                               
  pCK453            pACYCDuet-1 carrying *C. glutamicumthrBA16L*-*6his*, this study under P~T7~   in house                                                                                               
  pCK454            pACYCDuet-1 carrying *C. glutamicumthrBA16S*-*6his*, this study under P~T7~   in house                                                                                               

Plasmid Construction {#sec4.3}
--------------------

The *thrB-his* genes were amplified by PCR using ThrBFor and ThrBRev primers ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) and the *C. glutamicum* ATCC 13032 genomic DNA as a template. PCR product was cloned into the pACYCDuet-1 plasmid (Novagen) behind a T7 promoter. A20 of *CglthrB* was mutated to glycine, valine, serine, or leucine using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The *CglthrB-A20G* allele was PCR-amplified using primers c59g and c59g_antisense and pACYCDuet-1-P~T7~-*thrB*-*6his* as template. The *thrB-A20V* allele was amplified with c59t and c59t_antisense primers, the *thrB-A20S* allele with g58t and g58t_antisense, and the *thrB-A20L* allele with g58c_c59t and g58c_c59t_antisense primers. All plasmid and primers are listed in [Tables [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [2](#tbl2){ref-type="other"}, respectively.

###### Primers Used in This Work

  primer name           sequence
  --------------------- -----------------------------------------------------------------------------
  ThrBFor               5′-CCT CAT ATG GCA ATT GAA CTG AAC GTC-3′
  ThrBRev               5′-GGA CTC GAG CTA GTG GTG ATG ATG GTG GTG AGG TTG GTT AAC TTC AAC CTT G-3′
  c59g                  5′-TAC CTG GAT CTT CTG GAA ACC TCG GAC CTG G-3′
  c59g_antisense        5′-CCA GGT CCG AGG TCC AGA AGA TCC AGG TA-3′
  c59t                  5′-GTA CCT GGA TCT TCT GTA AAC CTC GGA CCT GGC-3′
  c59t_antisense        5′-GCC AGG TCC GAG GTT TAC AGA AGA TCC AGG TAC-3′
  g58t                  5′-GGT ACC TGG ATC TTC TTC AAA CCT CGG ACC TGG-3′
  g58t_antisense        5′-CCA GGT CCG AGG TTT GAA GAA GAT CCA GGT ACC-3′
  g58c_c59t             5′-GGT ACC TGG ATC TTC TCT AAA CCT CGG ACC TGG C-3′
  g58c_c59t_antisense   5′-GCC AGG TCC GAG GTT TAG AGA AGA TCC AGG TAC C-3′

Expression and Purification of the ThrB Proteins {#sec4.4}
------------------------------------------------

All constructs were used to transform *E. coli* BL21 (DE3), and transformants were grown in LB broth with 34 μg/mL chloramphenicol. Gene expression was induced with 1 mM isopropyl -[d]{.smallcaps}-1-thiogalactopyranoside at mid-log phase for 3 h at 37 °C. Cell pellets were stored at −80 °C until cells were lysed in a 1× PBS buffer containing protease inhibitors (Roche) by using a French Press (Thermo Scientific). Proteins were purified using Bio-Scale Mini Profinity IMAC Cartridges and the Profinia Protein Purification System (Bio-Rad). The proteins were then dialyzed overnight in 25 mM Tris pH 7.4. The purified proteins were then run on a sodium dodecyl sulfate polyacrylamide gel electrophoresis, stained with GelCode Blue (Pierce Biotechnology Inc.), and visualized on ChemiDoc XRS (Bio-Rad).

In Vitro Enzyme Assay and Kinetic Analysis of ThrB {#sec4.5}
--------------------------------------------------

Enzyme activity of ThrB (phosphorylation of [l]{.smallcaps}-homoserine) was determined in end-point assays by measuring a reaction product ADP via the ADP Colorimetric/Fluorometric Assay Kit (Sigma-Aldrich). Ultrapure ATP (Sigma-Aldrich) was diluted in 10 mM Tris-Cl, pH 7.0. Enzymes (*Cgl*ThrB-WT, *Cgl*ThrB-A20G, *Cgl*ThrB-A20V, *Cgl*ThrB-A20L, and *Cgl*ThrB-A20S) and [l]{.smallcaps}-homoserine were diluted in an assay buffer provided by the manufacturer. Each enzyme was assayed for 5 min at 27 °C using 40 nM enzyme, 1 mM [l]{.smallcaps}-homoserine, 2 mM ATP, 10 mM MgSO~4~, and 0.5 M KCl in 250 mM Tris pH 7.8 in a 96-well microtiter plate. The temperature was then shifted to 99 °C for 2 min to terminate the reaction. ADP assay buffer (Sigma-Aldrich) was added and further incubated at 27 °C for 30 min. The standard curve for ADP was obtained by incubating 0, 10, 20, 50, 100, and 200 μM of ADP in the ADP assay buffer. ADP concentrations were monitored by the MultiskanGO microplate spectrophotometer (Thermo Fisher Scientific) at 620 nm. Assays for the feedback inhibition were performed similarly using 5, 10, or 20 mM [l]{.smallcaps}-threonine.

Kinetic analysis of *Cgl*ThrB-WT and *Cgl*ThrB-A20G was conducted in similar reaction conditions, with addition of [l]{.smallcaps}-threonine at 0, 10, 20, or 50 mM concentrations. These reactions were assayed with 50, 100, 200, 500, and 1000 μM homoserine. Reads were taken at 30 s intervals. After incubating for 5 min (this condition was determined in a separate control experiment where the product homoserine-phosphate formation was still linearly proportional to incubation time), ThrB was inactivated by heating at 99 °C for 2 min. The concentration of ADP from each reaction was determined as described above, and *K*~m~ and *V*~max~ values were determined by using the SigmaPlot 12.5 (Systat software).

Crystallization of the *Cgl*ThrB-WT {#sec4.6}
-----------------------------------

The *Cgl*ThrB protein concentrated to 16.2 mg/mL in 20 mM Tris pH 7.5, 150 mM NaCl, 50 mM KCl, and 50 mM MgCl~2~ was used for crystallization experiments. Using the hanging-drop vapor diffusion method, *Cgl*ThrB crystals were grown with 2 μL of protein solution and 2 μL of well solution. Drops were equilibrated against 100 μL of well solution containing 0.25 M ammonium sulfate, 25% poly(ethylene glycol) 3350, and 0.1 M *N*-(2-hydroxyethyl)piperazine-*N*′-ethanesulfonic acid pH 7.5. Protein was co-crystallized with either methionine or ATPγS and cysteine for the 1.8 and 2.2 Å structures, respectively. No cryoprotectant was used for flash-freezing the crystals.

Diffraction Experiments and Structural Determination of *Cgl*ThrB-WT {#sec4.7}
--------------------------------------------------------------------

X-ray diffraction experiments were carried out at the LS-CAT beamline at the Advanced Photon Source of Argonne National Labs, Argonne, IL. The *Cgl*ThrB-WT structure was solved using diffraction data collected at a wavelength of 1.07819 Å. Diffraction data were integrated and scaled using HKL3000^[@ref24]^ ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}).

###### Data Collection and Refinement Statistics[a](#t3fn1){ref-type="table-fn"}

                              *Cgl*ThrB-hydrolyzed        *Cgl*ThrB full length
  --------------------------- --------------------------- --------------------------
  data collection                                         
  space group                 *P*4~1~2~1~2                *I*222
  cell dimensions                                         
  *a*, *b*, *c* (Å)           46.23, 46.23, 267.30        68.08, 130.08, 195.95
  α, β, γ (deg)               90, 90, 90                  90, 90, 90
  resolution (Å)              50.0--1.8                   50.0--2.2
  *R*~merge~                  0.052                       0.030
  *I*/σ(*I*)                  28.77 (6.40)                16.10 (3.25)
  completeness (%)            97.5 (95.2)                 99.8 (95.4)
  redundancy                  23.4 (19.5)                 4.7 (4.7)
  refinement                                              
  resolution (Å)              34.97--1.80                 42.34--2.14
  no. of unique reflections   27 709 (2 537)              48 115 (4 566)
  *R* ~work~/*R*~free~ (%)    24.14/28.71 (31.24/37.21)   19.84/23.66(20.75/25.62)
  no. of atoms                                            
  protein                     2058                        4553
  ligand/ion                  5                           65
  water                       61                          185
  *B*-factors (Å^2^)                                      
  protein                     49.50                       51.00
  ligand/ion                  47.00                       53.30
  water                       43.30                       44.50
  rms deviations                                          
  bond lengths (Å)            0.006                       0.009
  bond angles (deg)           1.040                       1.080
  Ramachandran                                            
  favored (%)                 96.22                       96.73
  outliers (%)                0.00                        0.00

The necessary data were obtained from one crystal. Values in parentheses are for the highest shells.

A search model for *Cgl*ThrB-WT was made on the basis of the 4rpf structure and used for molecular replacement using Phaser in PHENIX. Rigid body refinement, simulated annealing, positional, and *B*-factor refinements were performed using PHENIX.^[@ref25]^ Manual refinement of both structures was performed using COOT.^[@ref26]^
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Mja

:   *Methanocaldococcus jannaschii*

Mtb

:   *Mycobacterium tuberculosis*

Cgl

:   *Corynebacterium glutamicum*
